Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 3
1989 2
1990 2
1991 8
1992 4
1993 5
1994 13
1995 5
1996 8
1997 22
1998 26
1999 28
2000 33
2001 37
2002 37
2003 36
2004 32
2005 41
2006 52
2007 57
2008 54
2009 50
2010 56
2011 58
2012 65
2013 97
2014 164
2015 182
2016 172
2017 186
2018 192
2019 201
2020 216
2021 252
2022 309
2023 310
2024 363
2025 382
2026 91

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,437 results

Results by year

Filters applied: . Clear all
Page 1
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. Raulin AC, et al. Mol Neurodegener. 2022 Nov 8;17(1):72. doi: 10.1186/s13024-022-00574-4. Mol Neurodegener. 2022. PMID: 36348357 Free PMC article. Review.
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. ...
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to exten …
The neuropathological diagnosis of Alzheimer's disease.
DeTure MA, Dickson DW. DeTure MA, et al. Mol Neurodegener. 2019 Aug 2;14(1):32. doi: 10.1186/s13024-019-0333-5. Mol Neurodegener. 2019. PMID: 31375134 Free PMC article. Review.
Alzheimer's disease is a progressive neurodegenerative disease most often associated with memory deficits and cognitive decline, although less common clinical presentations are increasingly recognized. ...Other disease processes that are frequent, but …
Alzheimer's disease is a progressive neurodegenerative disease most often associated with memory deficits and cognitive …
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Jack CR Jr, et al. Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6. Lancet Neurol. 2010. PMID: 20083042 Free PMC article.
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. ...Neurodegeneration i …
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related t …
Mild cognitive impairment: clinical characterization and outcome.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Petersen RC, et al. Arch Neurol. 1999 Mar;56(3):303-8. doi: 10.1001/archneur.56.3.303. Arch Neurol. 1999. PMID: 10190820
PARTICIPANTS: A sample of 76 consecutively evaluated subjects with MCI were compared with 234 healthy control subjects and 106 patients with mild Alzheimer disease (AD), all from a community setting as part of the Mayo Clinic Alzheimer's Disease Center …
PARTICIPANTS: A sample of 76 consecutively evaluated subjects with MCI were compared with 234 healthy control subjects and 106 patients with …
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Jack CR Jr, et al. Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0. Lancet Neurol. 2013. PMID: 23332364 Free PMC article.
In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD). The model was received with interest because we described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clinical …
In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD). The model was received with …
Dual ontogeny of disease-associated microglia and disease inflammatory macrophages in aging and neurodegeneration.
Silvin A, Uderhardt S, Piot C, Da Mesquita S, Yang K, Geirsdottir L, Mulder K, Eyal D, Liu Z, Bridlance C, Thion MS, Zhang XM, Kong WT, Deloger M, Fontes V, Weiner A, Ee R, Dress R, Hang JW, Balachander A, Chakarov S, Malleret B, Dunsmore G, Cexus O, Chen J, Garel S, Dutertre CA, Amit I, Kipnis J, Ginhoux F. Silvin A, et al. Immunity. 2022 Aug 9;55(8):1448-1465.e6. doi: 10.1016/j.immuni.2022.07.004. Epub 2022 Aug 4. Immunity. 2022. PMID: 35931085 Free article.
We show that the previously identified disease-associated microglia (DAM) population detected in murine Alzheimer's disease models actually comprises two ontogenetically and functionally distinct cell lineages: embryonically derived triggering receptor expres …
We show that the previously identified disease-associated microglia (DAM) population detected in murine Alzheimer's disease …
TDP-43 Pathology in Alzheimer's Disease.
Meneses A, Koga S, O'Leary J, Dickson DW, Bu G, Zhao N. Meneses A, et al. Mol Neurodegener. 2021 Dec 20;16(1):84. doi: 10.1186/s13024-021-00503-x. Mol Neurodegener. 2021. PMID: 34930382 Free PMC article. Review.
Additionally, TDP-43 inclusions have been found in up to 57% of Alzheimer's disease (AD) cases, most often in a limbic distribution, with or without hippocampal sclerosis. ...
Additionally, TDP-43 inclusions have been found in up to 57% of Alzheimer's disease (AD) cases, most often in a limbic distrib …
Human iPSC 4R tauopathy model uncovers modifiers of tau propagation.
Parra Bravo C, Giani AM, Madero-Perez J, Zhao Z, Wan Y, Samelson AJ, Wong MY, Evangelisti A, Cordes E, Fan L, Ye P, Zhu D, Pozner T, Mercedes M, Patel T, Yarahmady A, Carling GK, Sterky FH, Lee VMY, Lee EB, DeTure M, Dickson DW, Sharma M, Mok SA, Luo W, Zhao M, Kampmann M, Gong S, Gan L. Parra Bravo C, et al. Cell. 2024 May 9;187(10):2446-2464.e22. doi: 10.1016/j.cell.2024.03.015. Epub 2024 Apr 5. Cell. 2024. PMID: 38582079 Free PMC article.
In progressive supranuclear palsy (PSP) and Alzheimer's Disease (AD) brains, the UFMylation cascade is altered in neurofibrillary-tangle-bearing neurons. ...
In progressive supranuclear palsy (PSP) and Alzheimer's Disease (AD) brains, the UFMylation cascade is altered in neurofibrill …
TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration.
Zhong L, Sheng X, Wang W, Li Y, Zhuo R, Wang K, Zhang L, Hu DD, Hong Y, Chen L, Rao H, Li T, Chen M, Lin Z, Zhang YW, Wang X, Yan XX, Chen X, Bu G, Chen XF. Zhong L, et al. Immunity. 2023 Aug 8;56(8):1794-1808.e8. doi: 10.1016/j.immuni.2023.06.016. Epub 2023 Jul 12. Immunity. 2023. PMID: 37442133 Free article.
Triggering receptor expressed on myeloid cells 2 (TREM2) is strongly linked to Alzheimer's disease (AD) risk, but its functions are not fully understood. Here, we found that TREM2 specifically attenuated the activation of classical complement cascade via high-affini …
Triggering receptor expressed on myeloid cells 2 (TREM2) is strongly linked to Alzheimer's disease (AD) risk, but its function …
APOE genotype determines cell-type-specific pathological landscape of Alzheimer's disease.
Li Z, Martens YA, Ren Y, Jin Y, Sekiya H, Doss SV, Kouri N, Castanedes-Casey M, Christensen TA, Miller Nevalainen LB, Takegami N, Chen K, Liu CC, Soto-Beasley A, Boon BDC, Labuzan SA, Ikezu TC, Chen Y, Bartkowiak AD, Xhafkollari G, Wetmore AM, Bennett DA, Reichard RR, Petersen RC, Kanekiyo T, Ross OA, Murray ME, Dickson DW, Bu G, Zhao N. Li Z, et al. Neuron. 2025 May 7;113(9):1380-1397.e7. doi: 10.1016/j.neuron.2025.02.017. Epub 2025 Mar 19. Neuron. 2025. PMID: 40112813
The apolipoprotein E (APOE) gene is the strongest genetic risk modifier for Alzheimer's disease (AD), with the APOE4 allele increasing risk and APOE2 decreasing it compared with the common APOE3 allele. ...
The apolipoprotein E (APOE) gene is the strongest genetic risk modifier for Alzheimer's disease (AD), with the APOE4 allele in …
3,437 results